<DOC>
	<DOCNO>NCT00983073</DOCNO>
	<brief_summary>The main objective study evaluate effectiveness , tolerability , safety tapentadol hydrochloride prolong release participant suffer severe chronic pain due osteoarthritis knee take either WHO Step I Step II analgesic regular analgesic . This clinical effectiveness trial design establish link anticipated clinical outcome clinical practice mean select measure clinical subject-reported outcome . The trial compare effectiveness previous analgesic treatment ( either WHO Step I Step II analgesic regular analgesic ) tapentadol hydrochloride prolonged release ( PR ) treatment define period evaluation .</brief_summary>
	<brief_title>Evaluation Effectiveness Tolerability Tapentadol Hydrochloride Subjects With Severe Pain Due Osteoarthritis Taking Either WHO Step I Step II Analgesics Regular Analgesic</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Chronic Pain</mesh_term>
	<mesh_term>Analgesics</mesh_term>
	<criteria>1 . Participants sign Informed Consent Form indicate understand purpose procedure require trial willing participate . 2 . Participants men nonpregnant , nonlactating woman . Sexually active woman must postmenopausal , surgically sterile , practice effective method birth control ( e.g. , prescription oral contraceptive , contraceptive injection , intrauterine device , double barrier method , contraceptive patch , male partner sterilization ) entry throughout trial . Women childbearing potential must negative pregnancy test screening . 3 . Participants must appropriately communicative verbalize differentiate regard location intensity pain . 4 . Participants must least 40 year age . 5 . Participants must diagnosis osteoarthritis knee base American College Rheumatology ( ACR ) classification criterion : Knee pain Radiographic osteophytes Knee pain Aged 40 year , Morning stiffness le 30 minute duration Crepitus motion . 6 . Participants must pain reference joint present least 3 month . 7 . Participant 's pain must require strong analgesic ( define WHO Step III ) judge Investigator . 8 . Participants must report rate satisfaction previous analgesic regimen exceed `` fair '' participant satisfaction treatment scale ( 5point VRS ) . 9 . If regular , daily pretreatment : Participants must take WHO Step I Step II analgesic medication osteoarthritis knee daily basis least 2 week prior Screening Visit . The Investigator considers dose increase WHO Step I analgesics ( mono combination therapy ) and/or continuation dose increase WHO Step II analgesic inadequate individual participant , whatever applicable . Participants must average pain intensity score ( NRS 3 ) great 5 point last 3 day prior Screening Visit . OR regular analgesic pretreatment report : Participants must average pain intensity score ( NRS3 ) great 6 point last 3 day prior Screening Visit related osteoarthritis . 1 . Presence clinically significant disease laboratory finding Investigator 's opinion may affect efficacy safety assessment . 2 . Presence active systemic local infection , may , opinion Investigator , affect efficacy , quality life/function safety assessment . 3 . History alcohol drug abuse , suspicion thereof Investigator 's judgment . 4 . Presence concomitant autoimmune inflammatory condition . 5 . Known history laboratory value reflect severe renal impairment . 6 . Known history moderately severely impaired hepatic function . 7 . History active hepatitis B C within past 3 month history HIV infection . 8 . History seizure disorder epilepsy . 9 . Any follow within 1 year : mild/moderate traumatic brain injury , stroke , transient ischemic attack , brain neoplasm . Severe traumatic brain injury within 15 year ( consist 1 following : brain contusion , intracranial hematoma , either unconsciousness posttraumatic amnesia last 24 h ) residual sequela suggest transient change consciousness . 10 . Pregnant breastfeeding . 11 . History allergy , hypersensitivity tapentadol hydrochloride excipients , contraindication relate tapentadol hydrochloride include : Participants acute severe bronchial asthma hypercapnia . Participants suspect paralytic ileus . 12 . Employees Investigator trial site , direct involvement trial trial direction Investigator trial site , well family member employee Investigator . 13 . Participation another trial concurrently within 4 week prior Screening Visit . 14 . Known suspect able comply protocol use investigational medicinal product . 15 . Use monoamine oxidase inhibitor within 14 day Screening Visit . 16 . Nonstable dose selective serotonin reuptake inhibitor within 30 day Screening Visit ( Doses must remain stable trial ) . 17 . Osteoarthritis flare state . 18 . Use intraarticular injection hyaluronic acid reference joint within 3 month Screening Visit . 19 . Presence condition osteoarthritis reference joint could confound assessment selfevaluation pain , e.g. , anatomical deformity , significant skin condition abscess syndrome widespread pain fibromyalgia . Participants osteoarthritis joint reference joint exclude long reference joint source main pain disability . 20 . History clinical sign reference joint crystalinduced ( e.g. , gout , pseudogout ) , metabolic , infectious autoimmune disease . 21 . Any concomitant painful condition could interfere participant ' trial assessment ability differentiate current joint pain painful condition . 22 . Any painful procedure trial ( e.g. , major surgery , include reference joint ) may , opinion Investigator , affect efficacy safety assessment . 23 . Pending litigation due chronic pain disability . 24 . Intake Step III analgesic within 30 day prior Screening Visit .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Osteoarthritis</keyword>
	<keyword>Pain</keyword>
	<keyword>Assessment</keyword>
	<keyword>Tapentadol</keyword>
	<keyword>Centrally act analgesic</keyword>
	<keyword>Chronic pain due osteoarthritis</keyword>
</DOC>